Resources


March 27, 2020

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint Development Agreement (the “MJDA”) with AzarGen ...

Continue Reading

March 26, 2020

iBio Announces Advancement of COVID-19 Vaccine Program

Preclinical Immunization Studies at Texas A&M University NEW YORK, March 26, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced ...

Continue Reading

March 20, 2020

iBio Joins the Alliance for Biosecurity

NEW YORK, March 20, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that it has joined the Alliance for Biosecurity, a ...

Continue Reading

March 18, 2020

iBio Announces Development of Proprietary COVID-19 Vaccine Candidates

Several Provisional Patents Filed with USPTO NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced its progress ...

Continue Reading

March 13, 2020

iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO

NEW YORK, March 12, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a ...

Continue Reading
1 2 3